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Abstract: During the co-evolution of cytomegalovirus (CMV) and natural killer (NK) cells, 
each has evolved specific tactics in an attempt to prevail. CMV has evolved multiple 
immune evasion mechanisms to avoid detection by NK cells and other immune cells, 
leading to chronic infection. Meanwhile, the host has evolved virus-specific receptors to 
counter these evasion strategies. The natural selection of viral genes and host receptors 
allows us to observe a unique molecular example of "survival of the fittest", as virus and 
immune cells try to out-maneuver one another or for the virus to achieve détente for optimal 
dissemination in the population. 
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Introduction 
During the course of evolution, the mammalian immune system has learned to adapt in order to 
defend the host against invading pathogens. Over time, lymphocytes of the immune system have 
acquired antigen-specific receptors as part of their arsenal to provide host immune surveillance against 
foreign substances and combat infectious agents. Some receptors, which arise by gene rearrangement 
and somatic hypermutation, can be exquisitely specific for processed protein fragments presented on 
major histocompatibility complex (MHC) molecules (in the case of T cells) or entire pathogen proteins 
(in the case of B cells and antibodies). Other receptors on innate immune cells, such as dendritic cells 
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and macrophages, are germline-encoded, such as the pattern recognition receptors (PRR), and 
recognize motifs or conserved molecular patterns present on microorganisms. Natural killer (NK) cells 
possess many other activating and inhibitory receptors, and specific ligation of these receptors 
determines whether or not NK cells become activated (reviewed in [1]). Recently, several activating 
receptors on NK cells have been shown to recognize pathogen components, but only a handful of these 
receptor-ligand interactions have been characterized. In addition, NK cells possess the activating 
NKG2D receptor, which recognizes host-encoded MHC class I-related proteins that are expressed on 
“stressed” cells, including virus-infected and transformed cells[1,2]. 
Whereas antibodies and B cells can recognize the intact pathogen, T cells require the pathogen 
components to be processed into short peptide fragments by antigen-presenting cells, and then the 
primed effector T cells require the pathogen-infected cells to present these pathogen-encoded peptides 
– MHC complexes to be displayed on the surface of the infected cell for T cell recognition and 
response. The means by which NK cells recognize certain pathogens has not been entirely elucidated. 
In mammals, there are different families of receptors on NK cells that serve similar functions. In mice 
and humans, convergent evolution has resulted in the Ly49 and KIR (Killer cell Immunoglobulin-like 
Receptor) families of receptors, respectively, both containing inhibitory members that recognize host 
MHC class I and activating receptors that might detect pathogen-infected cells[1]. To date, the ligands 
of most of the activating receptors have not been well characterized, but some are thought to be 
proteins specifically encoded by pathogens. Because we are constantly bombarded with environmental 
pathogens, there is evidence that selective pressures from virulent microbes have caused the immune 
system in higher organisms to evolve accordingly. For example, African population studies examining 
areas historically endemic for malaria demonstrated that Plasmodium falciparum infection in humans 
has been a driving force for the selection of various host immune system genes, such as certain human 
leukocyte antigen (HLA) alleles, important for protection against infection [3,4].  
The selective pressures that drive cells of the immune system to change over time are at work on the 
pathogen as well. In order to avoid immune detection and survive, viruses have adopted many immune 
evasion strategies such as blocking expression of molecules (MHC class I and NKG2D ligands) that 
“announce” the presence of infection or stress, and at the same time viruses carry in their genomes 
many decoy molecules (such as MHC class I analogs) that can inhibit cells of the immune system from 
becoming activated (reviewed in [5]). Only by delaying the response mounted by the immune cells or 
evading the immune system entirely can the virus ensure its own propagation and survival. This review 
will discuss several known NK cell receptor-pathogen interactions, focusing specifically on 
cytomegalovirus infections in mouse and human. 
Cytomegaloviruses evade the immune system 
The goal of CMV is to avoid elimination by the host immune response so that the virus can persist 
and be optimally disseminated in the host species population. To achieve this objective CMV, a large 
double-stranded DNA virus in the -herpesvirus family, has evolved a large number of genes that 
prevent recognition of infected cells by the immune system.  
During viral infection, CD8+ T cells can recognize viral peptides presented on MHC class I and 
mount a robust response by eliminating infected cells. Thus, CMV would benefit by blocking the 
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pathways leading to host presentation of viral peptides. Many CMV gene products inhibit the 
presentation of viral proteins on MHC class I [5,6]. The viral proteins m04, m06, and m152 found in 
MCMV disrupt the MHC class I synthesis pathway (m152 causes MHC class I retention in the pre-
Golgi compartment and m06 directs it to the lysosomes for degradation) and modulate antigen 
presentation (m04 escorts select MHC class I molecules to the cell surface) [7-12]. Similarly, HCMV 
US2, US3, US6, and US11 downregulate MHC class I presentation at different stages of biosynthesis; 
US2 and US11 drive retro-translocation of MHC class I from ER to the cytosol leading to degradation, 
US3 causes its retention in the ER, and US6 inhibits TAP-mediated transport of processed peptides for 
loading onto MHC class I [13-19]. These MCMV- and HCMV-encoded proteins and their location of 
function are depicted in Figure 1. 
Figure 1. MCMV and HCMV proteins interfere with MHC class I presentation and host 
recognition of virally infected cells. MCMV-encoded glycoproteins (shown in orange) inhibit the 
biosynthesis and expression of mouse MHC class I molecules: m06 binds MHC class I in the 
endoplasmic reticulum (ER) and redirects it to lysosomes leading to degradation, m152 retains 
MHC class I in an ER-to-Golgi intermediate compartment, and m04 forms a complex with MHC 
class I in the ER and together they are transported to the cell surface. HCMV-encoded 
glycoproteins (shown in red) also inhibit the biosynthesis and expression of human MHC class I 
molecules: US6 prevents translocation of proteasome-generated peptides from entering the ER via 
TAP (a specific transporter of peptides for loading on MHC class I molecules, associated with 
antigen presentation), US3 retains MHC class I in the ER, and US2 and US11 both bind MHC class 
I in the ER and mediate retro-translocation of molecules back to the cytoplasm via the Sec61 
channel leading to proteasomal degradation. 
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During viral infection, another mechanism by which the host can communicate “danger” to the 
immune system is through the expression of stress molecules. In humans, these stress markers include 
the MIC and ULBP (also referred to as RAET1) family of molecules, which are ligands for the 
activating NKG2D receptor on NK cells and T cells [20-23]. In mice, the RAE-1 family of gene 
products, along with MULT1 and H60, constitute the stress-induced ligands of NKG2D, which are 
strongly induced during viral infection[24-27]. Although the mRNA transcripts of these NKG2D 
ligands are highly upregulated during infection, MCMV and HCMV have evolved gene products to 
limit the protein expression of NKG2D ligands. In MCMV, the viral protein m152, in addition to 
modulating MHC class I expression, interferes with expression of all five members of the RAE-1 
family of glycoproteins [28], and the m145 and m155 proteins have been shown to downregulate 
MULT1 and H60 expression, respectively [29-31]. More recently, the viral protein m138 (also known 
as fcr-1) has been shown to play a redundant role, and is able to promiscuously suppress surface 
expression of NKG2D ligands MULT1, H60, and RAE-1 [32,33]. Furthermore, m138 can also inhibit 
the expression of the costimulatory molecule CD80 (B7-1) on dendritic cells, leading to reduced CD8+ 
T cell priming against MCMV [34]. In HCMV, the viral glycoprotein UL16 downmodulates 
expression of the human NKG2D ligands MICB, ULBP1, and ULBP2 [23,35], and the virus-encoded 
UL142 shuts down expression of certain alleles of MICA to prevent NK cell recognition and killing 
[36,37]. More recently, Mandelboim and colleagues showed that HCMV also encodes a microRNA 
(named hcmv-miR-UL112) that specifically targets MICB transcripts for degradation, leading to 
decreased NKG2D binding and NK cell-mediated lysis of infected target cells[38]. These MCMV and 
HCMV-encoded proteins are depicted in Figure 2. Undoubtedly, additional virus-encoded proteins and 
microRNAs will be discovered that inhibit the ability of infected cells to signal the presence of the 
virus to NK cells and CD8+ T cells. 
Both MCMV and HCMV possess genes encoding MHC class I-like molecules in their genomes. 
These homologs of MHC class I might serve as decoy ligands and allow the virus to hide from NK 
cells, which can sense the loss of MHC class I on potential target cells. Because inhibitory NK cell 
receptors, such as the mouse Ly49 receptors and the human KIRs, interact with MHC class I 
molecules, herpesviruses carrying homologues of class I might attempt to shut down the NK cell 
response. 
NK cell-mediated resistance to MCMV in mice is genetically controlled. Previous genetic mapping 
studies showed that resistance to MCMV was restricted to the C57BL/6 and MA/My strains of mice 
[39-42]. The CMV-resistance gene(s), designated Cmv1r, is located on the distal end of mouse 
chromosome 6 [42-46], and this Cmv1r gene in C57BL/6 mice enables NK cells to protect mice from 
an otherwise lethal infection [41,47]. The precise molecular interactions between mouse NK cell 
receptors and viral elements on MCMV-infected cells have been elucidated, providing insights into the 
mechanisms behind NK cell-mediated anti-viral responses [48]. Similarly, a specific NK cell subset 
has been identified in humans that preferentially expands during HCMV infection, suggesting the 
parallel evolution of immune pathways in mouse and man that target members of the herpesvirus 
family. 
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Figure 2. MCMV and HCMV proteins interfere with expression of NKG2D ligands and host 
recognition of virally infected cells. (A) MCMV-encoded glycoproteins (shown in orange) inhibit 
the expression of mouse NKG2D ligands: m152 interferes with expression of all five members of 
the RAE-1 family, m145 prevents surface expression of MULT1, m155 causes degradation of H60, 
and m138 assists to block expression of RAE-1, MULT1, and H60. (B) HCMV-encoded 
components (shown in red) also inhibit the expression of NKG2D ligands: UL142 inhibits MICA 
expression, UL16 binds MICB, ULBP1, and ULBP2 in the Golgi, and the miR-UL112 microRNA 
targets MICB mRNA for degradation leading to diminished cell surface expression of MICB. 
 
 
Ly49H and MCMV 
The NK cell response against MCMV constitutes arguably the most well-characterized example of a 
virus driving the evolution of immune receptors, and reciprocally the host immune system selecting for 
more virulent strains of a virus. In C57BL/6 mice, NK cells bearing the activating Ly49H receptor 
confer resistance against MCMV infection. Genetic linkage analysis, in conjunction with depletion of 
specific NK cell subsets by monoclonal antibodies, demonstrated that CMV-resistance is mediated by 
the Ly49H receptor, which is encoded by the Cmv-1 locus [40,49,50]. The Ly49H receptor cannot 
signal on its own, but pairs via its transmembrane domain with an adapter molecule DAP12, which 
contains immunoreceptor tyrosine-based activation motifs (ITAMs) [51]. More recently, Ly49H has 
been shown to also pair with DAP10 [52-54], another adaptor molecule containing a YINM motif 
activating PI3-kinase and Vav1; signaling via DAP10 enhances DAP12-driven NK cell-mediated 
functions [53]. Thus, when Ly49H+ NK cells encounter MCMV-infected cells, the Ly49H receptor 
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signals via DAP12 (augmented by DAP10), leading to NK cell activation, secretion of cytokines, and 
killing of the infected target cells (Figure 3). Not surprisingly, DAP12-deficient mice and DAP12 + 
DAP10 doubly-deficient mice are susceptible to MCMV infection, due to diminished expression of 
Ly49H and an inability to transmit a full activation signal [53,55]. Similarly, Ly49H-deficient mice on 
a C57BL/6 background, which possess NK cells unable to respond specifically against MCMV, are 
susceptible to viral infection [56,57]. Conversely, transgenic expression of Ly49H confers protection 
against MCMV in genetically susceptible BALB/c mice [58]. Thus, the presence of the Ly49H 
receptor (with its associated signaling subunits) is necessary and sufficient to provide NK cell-
mediated resistance against MCMV infection. 
Figure 3. MCMV-encoded m157 leads to activation or inhibition depending on NK cell receptor 
expression. Following MCMV infection of a target cell (step 1), the m157 glycoprotein is 
expressed (step 2). NK cells from C57BL/6 mice express the activating Ly49H receptor (top half of 
figure), which associates with and signals through the ITAM-containing DAP12 adaptor molecule. 
Recognition of m157 by Ly49H-bearing NK cells (step 3) leads to activation via DAP12 (step 4), 
followed by cell-mediated cytotoxicity via perforin and granzymes (step 5), secretion of cytokines 
such as IFN- (step 6), and a clonal-like proliferation (step 7). In contrast, NK cells from 129/J 
mice express the ITIM-containing Ly49I receptor (bottom half of figure), which binds m157 on 
MCMV-infected cells, and become inhibited. 
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The m157 glycoprotein encoded by MCMV was identified as a ligand of Ly49H using NFAT-GFP 
reporter cells expressing the Ly49H – DAP12 receptor complex [59,60]. Direct binding of m157 to 
Ly49H was further confirmed by using m157-Ig fusion proteins, which stained Ly49H transfectants 
and NK cells endogenously expressing Ly49H [59]. Additionally, Ly49H+ NK cells were able to 
mediate cytotoxicity and secrete IFN- when co-cultured with target cells expressing m157, and these 
effector functions were abrogated by a neutralizing anti-Ly49H antibody [59,60]. The expression of 
m157 in fibroblasts infected with MCMV is not dependent on 2-microglobulin (2m) or TAP [59], 
demonstrating that m157 does not associate with MHC class I and is stably expressed on the surface of 
infected cells without a binding partner. The crystal structure of m157 has revealed homology to the 
nonclassical MHC class I family of molecules such as CD1d, H2-M3, and T22 [61]. When Ly49H-
bearing NK cells detect m157 on MCMV-infected cells, this interaction leads to NK cell activation and 
effector function, followed by robust proliferation of Ly49H+ NK cells [62,63] (Figure 3). Not 
surprisingly, MCMV mutants lacking m157 are more virulent, resulting in higher viral titers in 
C57BL/6 mice following infection [64]. 
The retention of a viral protein that specifically activates an immune response appears 
counterproductive to survival of the virus, so why would MCMV retain such a seemingly detrimental 
component in its genome? m157 is a MHC class I homolog; therefore, it may have evolved to engage 
inhibitory NK cell receptors and thus counteract viral proteins involved in blocking MHC class I 
expression leading to “missing self” recognition. Cytomegaloviruses possess many genes encoding 
immunoevasins that interfere with antigen presentation by preventing the assembly of MHC class I, or 
by retaining and degrading MHC class I (reviewed in [5,65]). Although inhibiting MHC class I 
presentation might protect the virus from a CD8+ T cell response (Figure 4A), the loss of MHC class I 
proteins on the surface of virus-infected cells could potentially lead to destruction by NK cells [66,67] 
(Figure 4B). Thus, downregulation of MHC class I by CMV might have forced the evolution of CMV-
encoded class I-like homologs to engage inhibitory receptors on NK cells [68,69]. Thus, sensing of the 
viral MHC class I decoys that replace the vacated host MHC class I might suppress the NK cell 
response (Figure 4C). In certain strains of mice, for example 129/J, m157 binds the inhibitory Ly49I 
receptor [59], potentially impairing the ability of NK cells expressing Ly49I to respond to MCMV 
infection (Figure 3). Ly49I binds to m157 with higher affinity than with the Ly49H receptor [61]. 
Moreover, Ly49I binds to m157 with higher affinity than to the H2 ligand of Ly49I [61]. A 
comparison of the Ly49i and Ly49h genes indicates that Ly49i is evolutionary older and that Ly49h 
arose from a Ly49i gene by gene duplication and conversion [70]. During its evolution from Ly49I, 
Ly49H retained the ability to bind m157 (Figure 4D), but lost affinity for binding H2 ligands. 
Remarkably, due to selective pressure exerted by the virus, the host adapted [70-72]. Natural selection 
dictates that the virus will continue to mutate (Figure 4E), and this is evidenced by the high degree of 
polymorphism found in the m157 gene from MCMV strains isolated from mice in the wild [73]. 
Furthermore, serial passage of MCMV in C57BL/6 mice leads to the escape of viral variants 
containing loss-of-function mutations in m157 [73,74]. Together, these studies provide evidence that 
NK cells bearing specific activating receptors can exert ample selective pressure on a DNA virus, such 
that it undergoes rapid mutation at the molecular level in order to ensure its ability to evade immune 
surveillance and allow it to propagate.  
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Figure 4. Selective pressures drive the evolution of virus and host genes. A model predicting the 
influence of natural selection on evolution of herpesviruses and NK cell receptors: (A) During 
infection, viral peptides presented on MHC class I are recognized by CD8+ T cells (CTL) and the 
infected cell is killed. (B) The virus evades the host immune response by evolving mechanisms to 
block MHC class I presentation. Although the CTL response is ineffective due to loss of antigen 
presentation, NK cells sense “missing self” (lack of MHC class I) and kill the infected cell because 
they are not inhibited. (C) The virus evades NK cell surveillance by the acquisition of a MHC class 
I decoy molecules (i.e. molecular mimicry), which bind inhibitory receptors on NK cells. Neither 
the CTL nor NK cell can kill the infected cell. (D) The host immune system evolves. NK cells 
acquire an activating receptor that recognizes the viral MHC class I decoy via duplication and gene 
conversion of the inhibitory receptor; NK cells now specifically recognize the viral component and 
kill the infected cell. (E) The virus evolves and continues to evade the host immune system, by 
mutating the decoy MHC class I molecule so that NK cells can no longer recognize or kill the 
infected cell. 
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Ly49P and MCMV 
Although MA/My mice do not possess the Ly49h gene, these mice are resistant to MCMV. Vidal 
and colleagues demonstrated that epistatic interactions between the activating NK cell receptor Ly49P 
and host MHC class I H2-Dk confer resistance to MCMV in MA/My mice [39], which possess both. 
Genetic mapping studies revealed that to resist MCMV infection mice must inherit both the Ly49p and 
H2dk genes from their parents [39]. Similar to the Ly49H receptor, Ly49P associates with and signals 
through DAP12; however, unlike m157 detection by Ly49H, the virus-derived ligand recognized by 
Ly49P is not as straightforward. NFAT-GFP reporter cells expressing Ly49P and DAP12 were 
activated only when co-cultured with MCMV-infected fibroblasts that expressed H2-Dk and 
recognition was blocked by a neutralizing anti-H2-Dk antibody, but not antibody to H2-Kk [39]. Thus, 
Ly49P recognition of MCMV is MHC-restricted, similar to MHC-restriction of T cells. 
Recently, Vidal and colleagues identified a viral component required for Ly49P recognition of 
MCMV-infected cells. The virus-encoded m04 glycoprotein (also known as gp34) is crucial to NK 
cell-mediated control of viral replication, as a m04 deletion mutant of MCMV abrogated resistance 
against infection in MA/My mice [75]. Thus, both H2-Dk and m04 are required for NK cell-mediated 
protection against MCMV infection. Using chimeric molecules of H2, where the 1, 2, and 3 
domains of Db and Dk were systematically exchanged, Vidal and colleagues demonstrated that the 
peptide-binding 1 and 2 domains of H2-Dk are absolutely required for recognition by Ly49P 
reporter cells [75]. However, Ly49P reporter cells were not activated when co-cultured with fibroblasts 
only expressing m04 and H2-Dk in the absence of MCMV infection [75]. Therefore, the ligand 
recognized by Ly49P appears to require additional elements conferred by MCMV infection. Together, 
these data suggest that unlike the ability of m157 to directly activate Ly49H+ NK cells, m04 is required 
but not sufficient for recognition by Ly49P. Interestingly, m04 associates with MHC class I proteins in 
MCMV-infected cells [7-9,76], and is able to inhibit antigen presentation without reducing the amount 
of MHC class I at the cell surface [77,78]. 
What is the nature of the ligand for Ly49P? Although prior studies using recombinant Ly49P 
demonstrated low affinity binding of Ly49P to H-2, Ly49P reporter cells do not recognize fibroblasts 
expressing H2-Dk with endogenous peptides [75] (Figure 5A). During MCMV infection, TAP, 2m, 
and the peptide binding groove (1 and 2 domains) of H2-Dk are all required for Ly49P interaction, 
suggesting that Ly49P might recognize a peptide fragment of m04 bound to H2-Dk in manner similar 
to TCR recognition of peptide-MHC class I complexes (Figure 5B). Although this hypothesis remains 
plausible, the transfection of m04 into H2-Dk-bearing fibroblasts without MCMV infection did not 
stimulate Ly49P reporter cells [75]. By interactions requiring its transmembrane domain, m04 has been 
shown to physically associate with 2m and MHC class I heavy chain in the endoplasmic reticulum 
prior to transport to the cell surface [8,9,76]. During MCMV infection, m04 could conceivably modify 
the conformation of H2-Dk so that Ly49P can recognize an altered form of H2-Dk (Figure 5C). 
Although expression of m04 in MCMV-infected fibroblasts does not appear to hinder recognition by 
CD8+ T cells (implying minimal allosteric changes in MHC class I) [79], NK cell recognition of a 
m04-associated H2-Dk protein could be entirely different, and does not exclude normal binding of 
peptides to the MHC class I groove or recognition of viral peptide-MHC by the T cell receptor. 
Alternatively, Ly49P might recognize the entire m04/H2-Dk complex, with the extracellular C-type 
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lectin-like domains of Ly49P contacting both the intact viral m04 protein and the H2-Dk molecule 
(Figure 5D). Crystallization of the receptor bound to the ligand complex will reveal the nature of the 
viral ligand, as well as the specific amino acid residues on H2-Dk that are required both for m04 
association and for Ly49P recognition during MCMV infection. 
Figure 5. Possible mechanisms behind Ly49P recognition of m04 and H2-Dk during MCMV 
infection. (A) In the absence of MCMV infection, DAP12-associated Ly49P does not interact with 
MHC class I H2-Dk presenting endogenous peptides. (B) During MCMV infection, Ly49P-bearing 
NK cells might recognize a m04-derived peptide associated with H2-Dk. (C) During MCMV 
infection, Ly49P might interact with a H2-Dk molecule that has undergone a conformational change 
because of m04 binding (the altered self-MHC class I is labeled in the diagram as Dk*). (D) During 
MCMV infection, Ly49P-bearing NK cells might recognize the entire m04/H2-Dk complex, with 
the extracellular domains of Ly49P interacting with portions of both m04 and H2-Dk. 
 
 
Similar to the extensive polymorphism observed in the m157 gene found in MCMV isolates from 
wild mice, the high degree of variability of the m04 amino acid sequence in multiple strains of MCMV 
suggests that mutation of this gene constitutes a mechanism by which the virus responds to selective 
pressures mediated by the host immune system [80]. Not surprisingly, the highest degree of 
polymorphism was found to reside in the extracellular domains of the m04 protein (where Ly49P 
might contact m04), whereas the transmembrane and cytoplasmic regions remained relatively 
conserved [80]. Selective pressure and consequent evolution of m04 in MCMV strains from wild mice 
suggest that the host immune system can drive rapid mutation in specific viral proteins.  
If the m04 protein confers recognition by Ly49P and enhances killing of infected cells, why does 
MCMV retain such a protein? Three possibilities exist. First, m04 might counteract the diminished cell 
surface expression of MHC class I mediated by the viral glycoproteins m152 and m06, which retain 
and mediate degradation of MHC class I proteins, respectively [7,10-12]. Because both m152 and m06 
result in the loss of MHC class I on the cell surface, this might render MCMV-infected cells more 
susceptible to killing by NK cells able to sense “missing self”. Secondly, because m04 can selectively 
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escort and stabilize MHC class I on the surface of infected cells, inhibitory NK cell receptors might 
gain more access to MHC class I, leading to suppression of NK cell responses. Several MHC class I 
molecules (including H2-Kb and H2-Db) have been shown to form complexes with m04 [8,9], and 
these same MHC class I molecules have been shown to be specific ligands for different inhibitory NK 
cell receptors, including Ly49A, Ly49C, Ly49I, Ly49J, and Ly49V [81-84]. Lastly, it has been 
recently proposed that the m04 regulation of antigen presentation may enhance adaptive immune 
responses leading to host survival [85]; the outcome, although favorable to the host, may benefit the 
virus as well, allowing MCMV to be disseminated within the population. 
CD94-NKG2C and HCMV 
The first evidence that NK cells in humans were important for specific protection against 
cytomegalovirus came in 1989, when Biron and colleagues described a case of severe herpesvirus 
infection in a child lacking NK cells [86]. Unlike in the mouse models of cytomegalovirus infection 
described above, no specific viral ligands or NK cell receptors has yet been identified and 
characterized in HCMV. However, Lopez-Botet and colleagues have described the expansion of a 
specific subset of NK cells in response to HCMV. In the initial study, a substantial increase in the 
percentage of CD94-NKG2C receptor-expressing NK cells was observed in HCMV-seropositive 
individuals compared to control healthy adult blood donors [87]. One of the many difficulties of 
studying infectious diseases in humans is that it is hard to know when infection begins; therefore 
broadly characterizing immune cell subsets of HCMV-seropositive individuals only gives us snapshots 
of the immune response occurring days or months or even years after infection. Nonetheless, greater 
than 25% of the NK cells in HCMV-seropositive individuals expressed the activating NKG2C 
receptor, whereas the same subset of NK cells is rare (less than 2%) in seronegative subjects [87,88]. 
No such correlation between NK cell receptor expression and HCMV seropositivity was found for the 
related inhibitory NKG2A receptor [87,88]. Kuijpers and colleagues recently corroborated these results 
in a report describing preferential expansion of NKG2C+ NK cells in an immunodeficient child acutely 
infected with HCMV [89]. In this individual case, the time course of infection could be approximated 
and the peak of viremia closely correlated with the highly elevated NK cell numbers. Interestingly, the 
magnitude and kinetics of NK cell expansion and contraction closely resembles our recent 
measurements in the mouse Ly49H+ NK cell response following MCMV infection [63]. 
The human CD94-NKG2C receptor complex, expressed on NK cells and certain subsets of T cells, 
belongs to the killer C-type lectin-like receptor (KLR) family encoded in the NK cell gene complex on 
human chromosome 12 [46], and includes the NKG2A and NKG2C molecules which covalently 
associate with CD94 [90-94]. The CD94-NKG2A heterodimer is an inhibitory receptor that recruits the 
phosphatase SHP-1 via the immunoreceptor tyrosine-based inhibitory motif (ITIM) found in the 
cytoplasmic tail of NKG2A [95-98]. In contrast, the CD94-NKG2C heterodimer is activating, 
signaling via the associated ITAM-containing DAP12 subunit [99]. Both the inhibitory NKG2A and 
the activating NKG2C bind to a nonclassical MHC class Ib molecule HLA-E [100-102], which 
presents leader peptides derived from certain HLA-A, -B, -C, and -G proteins [100,103-105]. The 
affinity of NKG2A for HLA-E is 6-fold higher than the affinity of NKG2C. HLA-E is selectively 
resistant to downmodulation by the HCMV proteins that interfere with classical HLA class I 
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expression. A leader segment from the UL40 HCMV protein can bind HLA-E, potentially inhibiting 
activation of CD94-NKG2A-bearing NK cells during HCMV infection [106-109]. Perhaps because of 
its restricted peptide-binding ability, HLA-E does not induce a robust CD8+ T cell response. Therefore, 
by selectively preserving expression of HLA-E, HCMV might avoid CTL detection, yet suppress NK 
cell-mediated responses (Figure 6).  
Figure 6. NK cell recognition of HCMV-encoded proteins during infection. The HCMV-encoded 
UL40 protein contains an epitope (from the UL40 leader sequence) that is bound by HLA-E and 
presented at the surface of virally infected cells. Binding of UL40 peptide/HLA-E by the inhibitory 
CD94/NKG2A receptor leading to NK cell inhibition could represent an immune evasion 
mechanism of HCMV. However, the activating CD94/NKG2C receptor might also engage the 
UL40 peptide/HLA-E complex (although with lower affinity) leading to NK cell activation. At the 
same time, the HCMV-encoded UL18 glycoprotein is expressed at the surface of infected cells and 
binds LIR-1, an inhibitory receptor, leading to inhibition of NK cell responses. (There is also 
evidence suggesting that the CD94/NKG2C may also recognize UL18, although a functional 
consequence for such an interaction is currently lacking.) 
 
 
NKG2C might represent the host’s response to CMV’s evasive maneuvers targeting NKG2A. 
Analysis of the genes encoding NKG2A and NKG2C in primates spanning greater than 35 million 
years of evolution suggests that both have been undergoing a “positive” selection indicative of host-
pathogen struggles [110]. Is viral modulation of HLA-E enough to drive selection of a NKG2C 
receptor specific for HCMV?  
The HCMV-encoded UL18 glycoprotein has structural homology to MHC class I, even associating 
with 2m [69,111]. UL18 binds with high affinity to leukocyte immunoglobulin-like receptor-1 (LIR-
1) (also named LILRB1, CD85j, and ILT2), expressed in high amounts on monocytes and 
macrophages, B cells, and a subset of NK cells [112,113] (Figure 6). UL18 binds LIR-1 with a 3-log 
higher affinity than HLA class I [114]. Curiously, fibroblasts infected with a mutant HCMV lacking 
UL18 were found to be less susceptible to NK cell-mediated lysis than fibroblasts infected with 
wildtype strains of HCMV [115], suggesting that UL18 might enhance, rather than inhibit, NK cell 
activation. However, expansion of NKG2C+ NK cells in vitro was not abrogated when co-cultured 
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with fibroblasts infected with mutant virus lacking UL18 compared to fibroblasts infected with strains 
containing UL18 [115]. Recent studies have demonstrated that NKG2C, but not NKG2A, weakly 
binds UL18 (KD ~10-100 M) [110]. Nonetheless, as yet there is no direct evidence that NK cells 
expressing a CD94-NKG2C receptor directly recognize UL18 as a functional ligand.  
Concluding Remarks 
Altogether, these findings show that immune surveillance by NK cells drives the selection of viral 
genes, and the ability of cytomegalovirus to reciprocally shape the NK cell receptor repertoire. Is this 
interplay between NK cells and CMV unique to CMV? As yet, there is no evidence that the NK cell 
receptors recognizing CMV, such as Ly49H or Ly49P, are involved in the control of any other viral 
pathogens. Reciprocally, viral proteins similar to m157 have not been detected, at least by 
computationally searching the genomes of any other pathogens. Unlike B cells and T cells that can 
generate new receptors by somatic gene recombination, NK cells possess only those receptors encoded 
by the germline. Therefore, selection of these receptors must act at the population level in the species, 
not within the individual. The remarkable diversity of the murine Ly49 genes and primate KIR genes 
suggests an intriguing ongoing interaction between the host and pathogens. Perhaps the microbes of 
most interest to NK cells will be those pathogens, such as herpesvirus, that are persistent in the host 
and require constant vigilance.  
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